MedTrace Logo

Study of SBP-101 in Pancreatic Cancer

NCT02657330 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-04-20

No results posted yet for this study

Summary

This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.

Conditions

Interventions

DRUG

SBP-101

Subcutaneous drug, escalating dose cohorts

Sponsors & Collaborators

  • Panbela Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne Gagnon, MD · Panbela Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02657330 on ClinicalTrials.gov